Exact Mass: 348.0303722
Exact Mass Matches: 348.0303722
Found 236 metabolites which its exact mass value is equals to given mass value 348.0303722,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Inosine 5'-monophosphate (IMP)
Inosinic acid, also known as inosine monophosphate, IMP, 5-inosinate or 5-IMP, belongs to the class of organic compounds known as purine ribonucleoside monophosphates. These are nucleotides consisting of a purine base linked to a ribose to which one monophosphate group is attached. IMP is also classified as a nucleotide (a nucleoside monophosphate). Inosinic acid exists in all living species, ranging from bacteria to plants to humans. IMP is widely used as a flavor enhancer. In the food industry it is known as E number reference E630. Inosinic acid can be converted into various salts including disodium inosinate (E631), dipotassium inosinate (E632), and calcium inosinate (E633). These three inosinate compounds are used as flavor enhancers for the basic taste umami. These inosinate salts are mostly used in soups, sauces, and seasonings for the intensification and balance of the flavor of meat. Inosinic acid is typically obtained from chicken byproducts or other meat industry waste. Inosinic acid or IMP is important in metabolism. It is the ribonucleotide of hypoxanthine and the first nucleotide formed during the synthesis of purine nucleotides. It can also be formed by the deamination of adenosine monophosphate by AMP deaminase. GMP is formed by the inosinate oxidation to xanthylate (XMP). Within humans, inosinic acid participates in a number of enzymatic reactions. In particular, inosinic acid can be converted into phosphoribosyl formamidocarboxamide; which is catalyzed by the bifunctional purine biosynthesis protein. In addition, inosinic acid can be converted into xanthylic acid; which is catalyzed by the enzyme inosine-5-monophosphate dehydrogenase 1. Origin: Microbe; Formula(Parent): C10H13N4O8P; Bottle Name:Inosine-5-monophosphate; PRIME Parent Name:Inosine-5-monophosphate; PRIME in-house No.:0258, Purines A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety. COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, COVID-19 Disease Map Acquisition and generation of the data is financially supported in part by CREST/JST. relative retention time with respect to 9-anthracene Carboxylic Acid is 0.056 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.057 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Inosinic acid is an endogenous metabolite.
2-O-(6-Phospho-alpha-mannosyl)-D-glycerate
2-O-(6-Phospho-alpha-mannosyl)-D-glycerate is an alpha-D-mannosylglycerate (MG) that is an intermediate in 2-O-alpha-mannosyl-D-glycerate degradation. It can be generated from 2-O-alpha-mannosyl-D-glycerate via the enzyme 2-O-alpha-mannosyl-D-glycerate transporting phosphotransferase system (mngA). 2-O-Alpha-mannosyl-D-glycerate is a natural extremolyte identified in microorganisms growing under extremely high temperatures up to 100 oC, and had been shown to protect proteins against various stress conditions such as heat, freezing, thawing, and drying. MG that is naturally occurring hyperthermophilic osmolytes, could be potential drug candidates or lead compounds against alpha,beta aggregation associated with Alzheimers disease(PMID: 18304694). In most organisms MG is produced from guanosine pyrophosphate mannose (GDP-alpha-D-mannose) via mannosyl-3-phosphoglycerate in two steps, catalyzed by the enzymes mannosyl-3-phosphoglycerate synthase and mannosyl-3-phosphoglycerate phosphatase. [HMDB] 2-O-(6-Phospho-alpha-mannosyl)-D-glycerate is an alpha-D-mannosylglycerate (MG) that is an intermediate in 2-O-alpha-mannosyl-D-glycerate degradation. It can be generated from 2-O-alpha-mannosyl-D-glycerate via the enzyme 2-O-alpha-mannosyl-D-glycerate transporting phosphotransferase system (mngA). 2-O-Alpha-mannosyl-D-glycerate is a natural extremolyte identified in microorganisms growing under extremely high temperatures up to 100 oC, and had been shown to protect proteins against various stress conditions such as heat, freezing, thawing, and drying. MG that is naturally occurring hyperthermophilic osmolytes, could be potential drug candidates or lead compounds against alpha,beta aggregation associated with Alzheimers disease(PMID: 18304694). In most organisms MG is produced from guanosine pyrophosphate mannose (GDP-alpha-D-mannose) via mannosyl-3-phosphoglycerate in two steps, catalyzed by the enzymes mannosyl-3-phosphoglycerate synthase and mannosyl-3-phosphoglycerate phosphatase.
Doxefazepam
N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives > N05CD - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
2-keto-3-deoxy-D-glycero-D-galacto-nononate 9-phosphate
(2R)-2-(alpha-D-glucopyranosyloxy)-3-(phosphonooxy)propanoic acid
Succisulfone
C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent
Inosine 2'-phosphate
Inosine 2-phosphate is an inosine nucleotide containing a pyrophosphate group esterified to C2 of the sugar moiety. Inosine 2-phosphate is a product of 2,3-cyclic-nucleotide 3-phosphodiesterase (EC 3.1.4.37). This enzyme (also called CNP) catalyzes the chemical reaction: nucleoside 2,3-cyclic phosphate + H2O <-> nucleoside 2-phosphate. 2,3-cyclic nucleotide 3-phosphodiesterase is a myelin-associated enzyme that makes up 4\\% of total CNS myelin protein, and is thought to undergo significant age-associated changes. The absence of CNP causes axonal swelling and neuronal degeneration. [HMDB] Inosine 2-phosphate is an inosine nucleotide containing a pyrophosphate group esterified to C2 of the sugar moiety. Inosine 2-phosphate is a product of 2,3-cyclic-nucleotide 3-phosphodiesterase (EC 3.1.4.37). This enzyme (also called CNP) catalyzes the chemical reaction: nucleoside 2,3-cyclic phosphate + H2O <-> nucleoside 2-phosphate. 2,3-cyclic nucleotide 3-phosphodiesterase is a myelin-associated enzyme that makes up 4\\% of total CNS myelin protein, and is thought to undergo significant age-associated changes. The absence of CNP causes axonal swelling and neuronal degeneration.
Daidzein sulfate
Glucose-6-phosphate lactate
[(2R,5R)-3,4-Dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
Flavour enhancer
Cloxazolam, (R)-
N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics > N05BA - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
Taiwanin C
A furonaphthodioxole that is furo[3,4:6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one substituted by a 1,3-benzodioxol-5-yl group at position 5. It is a naturally occurring lignan extracted from Taiwania cryptomerioides and found to be a potential inhibitor of COX2 expression.
Helioxanthin
A furonaphthodioxole that is furo[3,4:6,7]naphtho[1,2-d][1,3]dioxol-7(9H)-one substituted by a 1,3-benzodioxol-5-yl group at posiiton 10. It is a inhibitor of HBV, HCV and HSV-1 viruses.
2-[(4-Chlorophenyl)sulfonyl]-3-[(4,6-dimethylpyrimidin-2-yl)amino]acrylonitrile
C15H13ClN4O2S (348.04477080000004)
N-[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfamoyl)phenyl]acetamide
3(2-Chlorophenyl)-7-hydroxy-4-phenylcoumarin
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.266 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.265 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.268
18-Bromo-(17Z)-octadeca-17-ene-5,7,15-triynoic acid
Isobutyric acid (2,2:5,2-terthiophen-5-yl)methyl ester
5-acetoxymethylen-2-(4-acetoxy-but-3-inyl)-dithiophene|5-acetoxymethylen-2-<4-acetoxy-but-3-inyl>-dithiophene|Di-Ac-4-[5-(Hydroxymethyl)-[2,2-bithiophen-5-yl]]-3-butyn-1-ol
Di-Ac-4-[5-Methyl-[2,2-bithiophen]-5-yl]-3-butyne-1,2-diol
(8beta)-10-bromo-3-chloro-2,7-epoxychamigr-9-en-8-ol|rel-(2R,3S,5aR,9S,9aR)-7-bromo-3-chloro-2,3,4,5,9,9a-hexahydro-3,6,6,9a-tetramethyl-6H-2,5a-methano-1-benzoxepin-9-ol
(7E,13E,17E)-form-18-Bromo-7,13,17-octadecatriene-5,15-diynoic acid
1-Hydroxy-3-methyl-8,10-dimethoxy-9-chlorodibenz[b,e]oxepin-6,11-dione
7-Methoxy-2-phenyl-3-sulfooxy-chromen-4-on|7-methoxy-2-phenyl-3-sulfooxy-chromen-4-one|rhamnocitrin 3-sulphate
4-Bromophenol glucuronide|4-bromophenyl beta-D-glucopyranosiduronic acid|O1-(4-Brom-phenyl)-beta-D-glucopyranuronsaeure|O1-(4-bromo-phenyl)-beta-D-glucopyranuronic acid
Inosinic acid
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Inosinic acid is an endogenous metabolite.
18-bromo-9E,15E,17E-octadecatrien-5,7-diynoic acid
1,1-Binaphthyl-2,2-diyl hydrogenphosphate
C20H13O4P (348.05514280000006)
2-(2-Fluoro-4-iodophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
3-(trimethylsilyl)-2-naphthyl trifluoromethanesulfonate
alpha-(4-Methoxybenzoyl)-2-chloro-4-nitroacetanilide
C16H13ClN2O5 (348.05129580000005)
Methanone,(7-bromo-2,3-dihydro-1,4-benzodioxin-6-yl)(2-methoxyphenyl)-
C16H13BrO4 (347.99971580000005)
2,2,3,3,5,5,6,6-OCTAFLUORO-4,4-BIPHENYLDICARBONITRILE
1-(4-chloro-3-isocyanatobenzenesulfonyl)-1,2,3,4-tetrahydroquinoline
C16H13ClN2O3S (348.0335378000001)
1,3-DIAMINO-4-(HEPTAFLUOROISOPROPYL)BENZENE DIHYDROCHLORIDE
C9H9Cl2F7N2 (348.00309780000003)
4,4-DIHYDROXYOCTAFLUORODIPHENYL MONOHYDRATE
C12H4F8O3 (348.00326899999993)
(R)-(-)-1,1-Binaphthyl-2,2-diyl hydrogenphosphate
C20H13O4P (348.05514280000006)
(S)-(+)-1,1-Binaphthyl-2,2-diyl hydrogenphosphate
C20H13O4P (348.05514280000006)
Sorivudine
C471 - Enzyme Inhibitor > C2019 - Dihydropyrimidine Dehydrogenase Inhibitor D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent D004791 - Enzyme Inhibitors Sorivudine (BV-araU) is an orally active synthetic pyrimidine nucleoside antimetabolite agent. Sorivudine derives its antiviral activity from selective conversion by a specific thymidine kinase present in certain DNA viruses to nucleotides, which can in turn interfere with viral DNA synthesis[1].
N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide hydrochloride
METHYL 4-(3-(4-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)BENZOATE
C17H11F3N2O3 (348.07217319999995)
2-ETHOXY-5-[(MORPHOLINE-4-CARBONYL)-AMINO]-BENZENESULFONYL CHLORIDE
C13H17ClN2O5S (348.05466620000004)
4,6-Dichloro-5-(2-methoxyphenoxy)-2,2-bipyrimidine
1,2,3,4,5,6-Cyclohexanehexacarboxylic acid
C12H12O12 (348.03287520000003)
Pifithrin-β (hydrobromide)
Pifithrin-β hydrobromide (PFT β hydrobromide) is a potent p53 inhibitor with an IC50 of 23 μM.
3-(5-Cyano-2-hydroxy-1,4-dimethyl-6-oxo-1,6-dihydropyridin-3-ylazo)benzenesulfonicacid
Ethyl 4-(3-bromo-4-formylphenoxy)benzoate
C16H13BrO4 (347.99971580000005)
4-AMINO-5-(4-CHLOROPHENYLSULFONYL)-2-(PROPYLTHIO)THIAZOLE
C12H13ClN2O2S3 (347.98276680000004)
2,2,3,3,4,4-hexafluoro-1,5-pentyl dimethacrylate
C13H14F6O4 (348.07962360000005)
5-(4-chlorophenyl)-N-quinolin-6-ylfuran-2-carboxamide
(1S,4S)-(+)-2-Benzyl-2,5-diazabicyclo[2.2.1]heptane dihydrobromide
2,4-Dinitrophenyl 2-Deoxy-2-Fluoro-Beta-D-Glucopyranoside
C12H13FN2O9 (348.06050600000003)
4-AMINO-N-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)BENZAMIDE
N-([3,5-BIS(TRIFLUOROMETHYL)BENZOYL]OXY)-2-CHLOROETHANIMIDAMIDE
C11H7ClF6N2O2 (348.01002239999997)
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine
C15H10ClFN4O3 (348.04254319999995)
4-Oxo-2-phenyl-4H-chromen-3-yl 2-thiophenecarboxylate
6-(Trifluoromethyl)-2-pyridinemethanol 2-(4-methylbenzenesulfonate)
C14H13F3NO4S (348.05173540000004)
1-Piperazineethanol, 4-[(3-bromophenyl)sulfonyl]-
C12H17BrN2O3S (348.01431920000005)
3-(perfluorobutyl)-2-hydroxypropyl acrylate
C10H9F9O3 (348.04079519999993)
Diethyl2,6-bis(methylthio)-4-oxo-4H-thiopyran-3,5-dicarboxylate
1-Bromo-6-ferrocenylhexane 6-Ferrocenylhexyl bromide
4-hydroxy-2-oxo-N-[3-(trifluoromethyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
C17H11F3N2O3 (348.07217319999995)
5-[(6-Methoxy-1,3-benzothiazol-2-yl)amino]-3-methyl-2-thiophenecarboxylic acid ethyl ester
3-(2-Chlorophenyl)-7-hydroxy-4-phenylchromen-2-one
(5z)-3-(4-Chlorophenyl)-4-Hydroxy-5-(1-Naphthylmethylene)furan-2(5h)-One
2,4-Dinitrophenyl 2-Deoxy-2-Fluoro-Beta-D-Mannopyranoside
C12H13FN2O9 (348.06050600000003)
{[4-Amino-2-(3-chloroanilino)-1,3-thiazol-5-YL](4-fluorophenyl)methanone
Tolestan
N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics > N05BA - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
2,4-DINITROPHENYL-2-FLUORO-2-DEOXY-BETA-D-GLUCOPYRANOSIDE
C12H13FN2O9 (348.06050600000003)
3-deoxy-D-glycero-beta-D-galacto-nonulosonic acid 9-phosphate
A ketoaldonic acid phosphate that is 3-deoxy-D-glycero-beta-D-galacto-nonulosonic acid carrying a monophosohate substituent at position 9.
[5-(2,6-dioxo-3H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
(2R)-3-phosphonooxy-2-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropanoic acid
[2,3,4,5-Tetrahydroxy-6-(phosphonooxymethyl)oxan-2-yl] 2-hydroxypropanoate
4-Chloro-6-[5-(4-ethoxyphenyl)-1,2,3-thiadiazol-4-yl]benzene-1,3-diol
C16H13ClN2O3S (348.0335378000001)
N-(bicyclo[2.2.1]hept-2-ylcarbonyl)-3-chloro-1-benzothiophene-2-carbohydrazide
5-[(3-chlorophenoxy)methyl]-N-(4-methyl-2-thiazolyl)-2-furancarboxamide
C16H13ClN2O3S (348.0335378000001)
4-Chloro-3-[[(2-methyl-3-nitrophenyl)-oxomethyl]amino]benzoic acid methyl ester
C16H13ClN2O5 (348.05129580000005)
({6-[4-(Methylsulfanyl)phenyl]thieno[3,2-d]pyrimidin-4-yl}sulfanyl)acetic acid
N1-Protonated adenosine-5-monophosphate
C10H15N5O7P+ (348.07090700000003)
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
3-(4-Bromoanilino)-1-(3-nitrophenyl)-1-propanone
C15H13BrN2O3 (348.01094880000005)
N-(1,3-dioxo-2-phenyl-5-isoindolyl)-2-thiophenecarboxamide
C19H12N2O3S (348.0568602000001)
4-chloro-3-nitrobenzaldehyde N-(4-methylphenyl)thiosemicarbazone
C15H13ClN4O2S (348.04477080000004)
4-[(2-oxo-3H-1,3-benzoxazol-6-yl)sulfonylamino]benzoic acid methyl ester
C15H12N2O6S (348.04160520000005)
3-(2-chloro-6-fluorophenyl)-N-(2-hydroxy-5-methylphenyl)-4,5-dihydroisoxazole-5-carboxamide
N-[4-(4-fluorophenyl)-2-thiazolyl]-4-methylbenzenesulfonamide
C16H13FN2O2S2 (348.04024499999997)
N-[1-[(2-bromophenyl)methyl]-2-oxo-3-pyridinyl]butanamide
C16H17BrN2O2 (348.04733219999997)
N-[3-[(1,3-dioxo-5-isoindolyl)oxy]phenyl]-2-furancarboxamide
C19H12N2O5 (348.07461820000003)
2-[(5-amino-7-methyl-[1,2,4]triazolo[4,3-c]pyrimidin-3-yl)thio]-N-(4-chlorophenyl)acetamide
C14H13ClN6OS (348.05600380000004)
(3E)-N-(3,5-dichloroanilino)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine-3-carboximidoyl cyanide
2-(2,5-Dihydroxy-4-methoxyphenyl)-3,5,6,7-tetrahydroxychromen-4-one
7-chloro-5-(2-chlorophenyl)-3-methoxy-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
adenosine 5-monophosphate(1+)
C10H15N5O7P (348.07090700000003)
An organic cation that is the conjugate acid of adenosine 5-monophosphate (AMP) obtained by selective protonation at position N1 on the purine moiety.
BPR1M97
BPR1M97 is a dual-acting mu opioid receptor (MOP) and nociceptin-orphanin FQ peptide (NOP) receptor agonist with Ki values of 1.8 and 4.2 nM, respectively. BPR1M97 shows high potency and blood-brain barrier penetration, and produces potent antinociceptive effects[1].
(1r,5r,6s)-3-bromo-9-chloro-2,2,6,9-tetramethyl-7-oxatricyclo[6.3.1.0¹,⁶]dodec-3-en-5-ol
1,6,8c-trihydroxy-7ah,8ah,8bh-peryleno[1,2-b]oxirene-7,11-dione
7,13,17-trihydroxy-12-oxapentacyclo[11.8.0.0²,¹¹.0³,⁸.0¹⁶,²¹]henicosa-1,3,5,7,10,16,18,20-octaene-9,15-dione
(7e,13e,17e)-18-bromooctadeca-7,13,17-trien-5,15-diynoic acid
(1s,2r,2'r,4s,4's,5's,6r)-5'-bromo-4'-chloro-1,4,4'-trimethyl-3-methylidene-7-oxaspiro[bicyclo[4.1.0]heptane-2,1'-cyclohexan]-2'-ol
13-chloro-6,14-dihydroxy-4,7,12-trimethyl-10-oxo-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaene-15-carbaldehyde
(4s,6s,8r)-8,10,16,18-tetrahydroxy-5-oxahexacyclo[11.7.1.0²,¹².0³,⁹.0⁴,⁶.0¹⁷,²¹]henicosa-1(21),2,9,11,13,15,17,19-octaen-7-one
(8bs,8cr)-1,6,8c-trihydroxy-7ah,8ah,8bh-peryleno[1,2-b]oxirene-7,11-dione
5'-bromo-4'-chloro-1,4,4'-trimethyl-3-methylidene-7-oxaspiro[bicyclo[4.1.0]heptane-2,1'-cyclohexan]-2'-ol
(11r,13e)-4-chloro-5,7-dihydroxy-11-methyl-10,19-dioxatricyclo[14.2.1.0³,⁸]nonadeca-1(18),3,5,7,13,16-hexaen-9-one
8,10,16,18-tetrahydroxy-5-oxahexacyclo[11.7.1.0²,¹².0³,⁹.0⁴,⁶.0¹⁷,²¹]henicosa-1(20),2,9,11,13(21),14,16,18-octaen-7-one
(7ar,8ar,8bs,8cr)-1,6,8c-trihydroxy-7ah,8ah,8bh-peryleno[1,2-b]oxirene-7,11-dione
2-chloro-1,3,8-trihydroxy-6-(2-hydroxypropyl)anthracene-9,10-dione
3,6-dihydroxy-1a,7a-dihydro-2',4'-dioxaspiro[naphtho[2,3-b]oxirene-2,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',7',9',11'-pentaen-7-one
5,7'-dihydroxy-2',11'-dioxaspiro[naphthalene-1,3'-tetracyclo[6.4.1.0⁴,¹³.0¹⁰,¹²]tridecane]-4'(13'),5',7'-triene-4,9'-dione
(1r,5s,6r,8r,9s)-3-bromo-9-chloro-2,2,6,9-tetramethyl-7-oxatricyclo[6.3.1.0¹,⁶]dodec-3-en-5-ol
3-bromo-9-chloro-2,2,6,9-tetramethyl-7-oxatricyclo[6.3.1.0¹,⁶]dodec-3-en-5-ol
(1s,3s,4r,6s,8s,9r)-3-bromo-4-chloro-4,12,12-trimethyl-11-methylidene-7-oxatricyclo[6.3.1.0¹,⁶]dodecan-9-ol
3-bromo-4-chloro-4,12,13,13-tetramethyl-7,11-dioxatetracyclo[6.4.1.0¹,⁶.0¹⁰,¹²]tridecane
16-(2h-1,3-benzodioxol-5-yl)-3,5,13-trioxatetracyclo[7.7.0.0²,⁶.0¹¹,¹⁵]hexadeca-1,6,8,10,15-pentaen-14-one
8,12,17-trihydroxypentacyclo[10.7.1.0²,¹¹.0⁴,⁹.0¹³,¹⁸]icosa-2(11),4,6,8,13,15,17-heptaene-3,10,19-trione
methyl 4-chloro-8-hydroxy-3-methoxy-6-methyl-9-oxoxanthene-1-carboxylate
(13r)-7,13,17-trihydroxy-12-oxapentacyclo[11.8.0.0²,¹¹.0³,⁸.0¹⁶,²¹]henicosa-1,3,5,7,10,16,18,20-octaene-9,15-dione
3-bromo-4-chloro-4,11,12,12-tetramethyl-7-oxatricyclo[6.3.1.0¹,⁶]dodecan-10-one
(1as,7ar)-3,6-dihydroxy-1a,7a-dihydro-2',4'-dioxaspiro[naphtho[2,3-b]oxirene-2,3'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(13'),5',7',9',11'-pentaen-7-one
(1r,1'r,10'r,12'r)-5,7'-dihydroxy-2',11'-dioxaspiro[naphthalene-1,3'-tetracyclo[6.4.1.0⁴,¹³.0¹⁰,¹²]tridecane]-4'(13'),5',7'-triene-4,9'-dione
(3r,3'r,4's)-3'-bromo-1-chloro-2',2',6-trimethyl-6'-methylidene-7-oxaspiro[bicyclo[4.1.0]heptane-3,1'-cyclohexan]-4'-ol
2-amino-6-hydroxy-8-(4-hydroxybenzoyl)phenoxazin-3-one
C19H12N2O5 (348.07461820000003)